
Sun Pharma’s Leqselvi Holds Efficacy Edge Over Rivals, Sales to Touch $700 Mn by 2033: Experts
London: Having averted a patent challenge, Sun Pharma’s hair loss drug Leqselvi (deuruxolitinib) is poised to outperform rival treatments. It holds strong potential for rapid uptake in the US, with sales projected to reach approximately $698.3 million by …